{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ankylosing-spondylitis/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 289478ac-61fe-4662-8edd-fd78e06382fd --><h2>How common is it?</h2><!-- end field 289478ac-61fe-4662-8edd-fd78e06382fd -->","summary":"","htmlStringContent":"<!-- begin item cfb69bc9-bbf2-4f58-b184-f783f19feef7 --><!-- begin field b3bde452-bf3f-477a-9a97-20fcafa6cdb4 --><ul><li>Each year, a GP may only see one person presenting with new onset spondyloarthritis, making it a challenge to diagnose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].  <ul><li><strong>Prevalence</strong> of ankylosing spondylitis is believed to range from 0.05% to 0.23% [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2016</a>].<ul><li>A UK cross-sectional cohort study of 505 people found a prevalence of axial spondyloarthritis of 0.66% (using modified New York criteria) in an adult primary care population with low back pain, and 0.15% in the general adult primary care population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Hamilton et al, 2015</a>].  </li><li>Estimates of the prevalence of ankylosing spondylitis vary between countries with mean prevalence per 10,000 of 31.9 in North America, 23.8 in Europe, 16.7 in Asia, 10.2 in Latin America, and 7.4 in Africa [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Dean et al, 2014</a>]. Subsequent systematic reviews also found variable prevalence rates for ankylosing spondylitis between countries, but no studies reporting prevalence data for non-radiographic axial spondyloarthritis were identified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Stolwijk et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Bohn et al, 2018</a>]. </li></ul></li><li><strong>Sex. </strong>Around twice as many men have ankylosing spondylitis compared with women, although this varies depending on the study [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Dean et al, 2014</a>]. Non-radiographic axial spondyloarthritis affects a similar number of women as men [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Sieper and Poddubnyy, 2017</a>]. </li><li><strong>Age. </strong>It most commonly begins between 20 and 30 years of age, with 90–95% of people aged less than 45 years at disease onset [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Sieper, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Sieper and Poddubnyy, 2017</a>]. </li><li><strong>Familial association. </strong>Spondyloarthritis (particularly axial disease) is associated with the HLA-B27 antigen, although axial spondyloarthritis can occur in people without HLA-B27 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. The range in occurrence of spondyloarthritis across geographic regions has been attributed to the prevalence of HLA-B27 in different populations, although other factors in the studies such as mean age of the sample, the male:female ratio, and methodological features also contribute [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Stolwijk et al, 2016</a>].  </li></ul></li><li><strong>Extra-articular manifestations</strong> are common in people with ankylosing spondylitis. A systematic review and meta-analysis of worldwide data [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Stolwijk et al, 2015</a>] found a pooled prevalence for:<ul><li>Uveitis of 25.8% (95% CI 24.1 to 27.6).</li><li>Psoriasis of 9.3% (95% CI 8.1 to 10.6).</li><li>Inflammatory bowel disease of 6.8% (95% CI 6.1 to 7.7).</li></ul></li></ul><!-- end field b3bde452-bf3f-477a-9a97-20fcafa6cdb4 --><!-- end item cfb69bc9-bbf2-4f58-b184-f783f19feef7 -->","topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","lastRevised":"Last revised in May 2019","chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}